VENUSREM
Venus Remedies Ltd
Each stock's 10,000-path forecast, rendered as light.
Venus Remedies Ltd (VENUSREM) Stock Analysis & Case Study
What the numbers say about VENUSREM, and the method behind each one.
Venus Remedies Ltd (VENUSREM) trades at ₹1,729,on the numbers it worth a closer look, a Downstox Snapshot Score of 56/100.
On the numbers, Venus Remedies Ltd (VENUSREM) worth a closer look, a Downstox Snapshot Score of 56/100, weighing fairly valued at 19.8× earnings, ROE of 16.8%, a 49% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
VENUSREM fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How VENUSREM ranks against the 2,979 companies in our screener
- VENUSREM's market cap of 2,298 Cr ranks in the 62nd percentile of the 2,979 NSE companies in our screener, as of 13 Aug 2026.
- VENUSREM's book value of ₹497 ranks in the 92nd percentile of the 2,979 NSE companies in our screener, as of 13 Aug 2026.
- VENUSREM's promoter holding of 41.8% ranks in the 16th percentile of the 2,979 NSE companies in our screener, as of 13 Aug 2026.
- VENUSREM's 3-year profit (PAT) growth of 57.0% ranks in the 83rd percentile of the 2,979 NSE companies in our screener, as of 13 Aug 2026.
- VENUSREM's 3-year revenue growth of 12.0% ranks in the 52nd percentile of the 2,979 NSE companies in our screener, as of 13 Aug 2026.
- VENUSREM's debt-to-equity ratio of 0.02x is lower than 94% of the 2,979 NSE companies in our screener, as of 13 Aug 2026.
Is VENUSREM overvalued? VENUSREM P/E vs peers
VENUSREM trades at 19.8× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
VENUSREM share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of VENUSREM history (27%/yr drift, 51%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| VENUSREM 2027 | ₹931 | ₹1,769 | ₹3,361 | -2% |
| VENUSREM 2028 | ₹700 | ₹1,740 | ₹4,329 | -3% |
| VENUSREM 2029 | ₹560 | ₹1,712 | ₹5,233 | -5% |
| VENUSREM 2030 | ₹461 | ₹1,684 | ₹6,155 | -6% |
| VENUSREM 2031 | ₹390 | ₹1,657 | ₹7,040 | -8% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability VENUSREM goes up, or doubles?
The bull case for VENUSREM
- VENUSREM's P/E of 19.8x is lower than 58% of the 2,979 NSE companies in our screener, as of 13 Aug 2026.
- VENUSREM's return on equity of 16.8% ranks in the 74th percentile of the 2,979 NSE companies in our screener, as of 13 Aug 2026.
- VENUSREM's return on capital employed of 21.7% ranks in the 81st percentile of the 2,979 NSE companies in our screener, as of 13 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹5,233.
The bear case & risks
- High historical volatility (51%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹560.
VENUSREM volatility & expected range, how bumpy is the ride?
Over the last 9.8 years VENUSREM compounded at 27%/year with annualized volatility of 51%. That volatility implies a 1-year 80% range of ₹931-₹3,361, the honest backbone behind any single price target.
VENUSREM price forecast, the full 60-month probability fan
VENUSREM price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds VENUSREM hits common targets within the simulated horizon?
Full multi-horizon detail on the VENUSREM price target & forecast page.
VENUSREM Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. VENUSREM scores 6/8, mixed financial health.
About Venus Remedies Ltd: sector, index & market-cap context
Venus Remedies Ltd (VENUSREM) is a small-cap NSE-listed company, with a market capitalisation of ₹2,298 Cr. See more stocks on our screener.
How the VENUSREM Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Venus Remedies Ltd's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
VENUSREM analysis, FAQs
Is Venus Remedies Ltd (VENUSREM) a good buy?
On the numbers, Venus Remedies Ltd (VENUSREM) worth a closer look, a Downstox Snapshot Score of 56/100, weighing fairly valued at 19.8× earnings, ROE of 16.8%, a 49% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is VENUSREM overvalued or undervalued?
VENUSREM trades at 19.8× earnings, fairly valued versus the ~22× long-run Nifty average.
What is the VENUSREM share price target for 2031?
VENUSREM's probability-weighted 2031 median target is ₹1,657, with an 80% range of ₹390-₹7,040 (10,000-path Monte-Carlo).
What is the probability VENUSREM doubles in 5 years?
The modelled probability of VENUSREM reaching ₹3,596 (2×) within 5 years is 25%.
What is the bull case for VENUSREM?
VENUSREM's P/E of 19.8x is lower than 58% of the 2,979 NSE companies in our screener, as of 13 Aug 2026. VENUSREM's return on equity of 16.8% ranks in the 74th percentile of the 2,979 NSE companies in our screener, as of 13 Aug 2026. VENUSREM's return on capital employed of 21.7% ranks in the 81st percentile of the 2,979 NSE companies in our screener, as of 13 Aug 2026.
What are the risks in VENUSREM?
High historical volatility (51%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
More on VENUSREM
For information and education only. Downstox is a data and analytics platform, not a SEBI-registered Research Analyst or Investment Adviser. Nothing here is investment advice or a recommendation to buy, sell or hold any security. Any scores, ranks, targets or scenarios are model estimates shown with their method, not forecasts or assured outcomes. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing.